You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the DEFINITY RT (perflutren) Drug Profile, 2024 PDF Report in the Report Store ~

DEFINITY RT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Definity Rt patents expire, and what generic alternatives are available?

Definity Rt is a drug marketed by Lantheus Medcl and is included in one NDA. There are nine patents protecting this drug.

This drug has sixty-nine patent family members in seventeen countries.

The generic ingredient in DEFINITY RT is perflutren. One supplier is listed for this compound. Additional details are available on the perflutren profile page.

DrugPatentWatch® Generic Entry Outlook for Definity Rt

Definity Rt was eligible for patent challenges on July 31, 2005.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for DEFINITY RT
International Patents:69
US Patents:9
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 63
Formulation / Manufacturing:see details
Drug Prices: Drug price information for DEFINITY RT
What excipients (inactive ingredients) are in DEFINITY RT?DEFINITY RT excipients list
DailyMed Link:DEFINITY RT at DailyMed
Drug patent expirations by year for DEFINITY RT
Drug Prices for DEFINITY RT

See drug prices for DEFINITY RT

Recent Clinical Trials for DEFINITY RT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme LLCPhase 2
InSightecPhase 2
M.D. Anderson Cancer CenterPhase 2

See all DEFINITY RT clinical trials

Pharmacology for DEFINITY RT

US Patents and Regulatory Information for DEFINITY RT

DEFINITY RT is protected by nine US patents.

Patents protecting DEFINITY RT

Lipid-encapsulated gas microsphere compositions and related methods
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Lipid-encapsulated gas microsphere compositions and related methods
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods for making ultrasound contrast agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods and devices for preparation of ultrasound contrast agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods for making ultrasound contrast agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Lipid-encapsulated gas microsphere compositions and related methods
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods for making ultrasound contrast agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for DEFINITY RT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Lantheus EU Limited Luminity perflutren EMEA/H/C/000654
This medicinal product is for diagnostic use only.Luminity is an ultrasound contrast-enhancing agent for use in patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.
Authorised no no no 2006-09-20
GE Healthcare AS Optison perflutren EMEA/H/C/000166
This medicinal product is for diagnostic use only.Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left-ventricular-endocardial-border delineation with resulting improvement in wall-motion visualisation.Optison should only be used in patients where the study without contrast enhancement is inconclusive.
Authorised no no no 1998-05-17
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Supplementary Protection Certificates for DEFINITY RT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0712293 0790017-8 Sweden ⤷  Try a Trial PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920
0712293 300267 Netherlands ⤷  Try a Trial 300267, 20140520, EXPIRES: 20190519
0712293 CA 2007 00027 Denmark ⤷  Try a Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.